HER2-Negative Breast Cancer - Current and Future Players


#845846

96pages

GlobalData

$ 2995

In Stock

HER2-Negative Breast Cancer - Current and Future Players

Summary

GlobalData has released its pharma report, HER2-Negative Breast Cancer - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Insomnia Market. The report identifies and analyses the key companies shaping and driving the global Insomnia market. The report provides insight into the competitive Insomnia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for HER2-Negative Breast Cancer
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of HER2-Negative Breast Cancer sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving HER2-Negative Breast Cancer market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- Whats the next big thing in the global HER2-Negative Breast Cancer market landscape? Identify, understand and capitalize
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 6
2.3 Upcoming Related Reports 7
3 Market Outlook 8
3.1 Global Markets 8
3.1.1 Forecast 8
3.1.2 Drivers and Barriers - Global Issues 14
4 Current and Future Players 16
4.1 Overview 16
4.2 Trends in Corporate Strategy 18
4.3 Company Profiles 21
4.3.1 AstraZeneca 21
4.3.2 Bristol-Myers Squibb 22
4.3.3 Eli Lilly 24
4.3.4 Pfizer 25
4.3.5 Novartis/GlaxoSmithKline 28
5 Appendix 30
5.1 Bibliography 30
5.2 Abbreviations 57
5.3 Methodology 65
5.4 Forecasting Methodology 65
5.4.1 Diagnosed HER2-Negative Breast Cancer Patients 65
5.4.2 Percentage of Drug-Treated Patients 66
5.4.3 Drugs Included in Each Therapeutic Class 66
5.4.4 Launch and Patent Expiry Dates 67
5.4.5 General Pricing Assumptions 68
5.4.6 Individual Drug Assumptions 70
5.4.7 Generic Erosion 78
5.4.8 Pricing of Pipeline Agents 78
5.5 Primary Research - KOLs Interviewed for This Report 89
5.6 Primary Research - High-Prescriber Survey 91
5.7 About the Authors 92
5.7.1 Analyst 92
5.7.2 Director of Oncology 92
5.7.3 Epidemiologist 93
5.7.4 Director of Epidemiology 93
5.7.5 Global Head of Healthcare 94
5.8 About GlobalData 95
5.9 Disclaimer 95

1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for HER2-Negative Breast Cancer, 2013-2023 11
Table 2: Global HER2-Negative Breast Cancer Market - Drivers and Barriers, 2013-2023 14
Table 3: AstraZenecas, Breast Cancer Portfolio Assessment, 2014 22
Table 4: AstraZeneca SWOT Analysis, 2014 22
Table 5: BMS Breast Cancer Portfolio Assessment, 2014 24
Table 6: BMS SWOT Analysis, 2014 24
Table 7: Eli Lilly SWOT Analysis, 2014 25
Table 8: Pfizers Breast Cancer Portfolio Assessment, 2014 27
Table 9: Pfizer SWOT Analysis, 2014 27
Table 10: Novartis Breast Cancer Portfolio Assessment, 2014 29
Table 11: Novartis SWOT Analysis, 2014 29
Table 12: HER2-Negative Breast Cancer Incidence, 2013-2023 66
Table 13: Key Launch Dates of Marketed and Pipeline Drugs for HER2-Negative Breast Cancer 67
Table 14: Key Expiry Dates of Marketed and Pipeline Drugs Used in HER2-Negative Breast Cancer 68
Table 15: Average Body Weight and Surface Area Across the 8MM 69
Table 16: Cost per Treatment Cycle ($) - Abraxane, Metastatic Setting (HR+) 72
Table 17 Cost per Treatment Cycle ($) - Avastin, Metastatic Setting (HR+/TNBC) 73
Table 18: Cost per Treatment Cycle ($) - Afinitor, Third-Line Hormonal/ Targeted Therapy 74
Table 19: Cost per Treatment Cycle ($) - Doxil, Metastatic Setting (HR+/TNBC) 75
Table 20: Cost per Treatment Cycle ($) - Halaven, Metastatic Setting (HR+/TNBC) 76
Table 21: Cost per Treatment Cycle ($) - Ixempra, Metastatic Setting (HR+/TNBC) 77
Table 22 Cost per Treatment Cycle ($) - Xeloda, Metastatic Setting (HR+/TNBC) 78
Table 23: Cost per Treatment Cycle ($) - Abemaciclib, First-/Second-Line Hormonal/Targeted Metastatic Setting (HR+) 79
Table 24: Cost per Treatment Cycle ($) - Buparlisib, Postmenopausal Hormonal Neoadjuvant, Second- and Third-Line Hormonal/Targeted Metastatic Settings (HR+) 80
Table 25: Cost per Treatment Cycle ($) - Javlor, Third-Line Chemotherapy Metastatic Setting (HR+) 81
Table 26: Cost per Treatment Cycle ($) - LEE011, Postmenopausal Hormonal Neoadjuvan, and First-Line Hormonal/Targeted Metastatic Settings (HR+) 82
Table 27: Cost per Treatment Cycle ($) - NeuVax, Adjuvant Setting (HR+) 83
Table 28: Cost per Treatment Cycle ($) - Niraparib, Metastatic TNBC Setting 83
Table 29: Cost per Treatment Cycle ($) - NKTR-102, Third Line Chemotherapy Metastatic Setting (HR+) 84
Table 30: Cost per Treatment Cycle ($) - Lynparza, Adjuvant and First-Line Metastatic TNBC Settings 85
Table 31: Cost per Treatment Cycle ($) - Palbociclib, First- and Second-Line Hormonal/Targeted Metasatatic Setting (HR+) 86
Table 32: Cost per Treatment Cycle ($) - Talazoparib, Third-Line Metastatic TNBC Setting 87
Table 33: Cost per Treatment Cycle ($) - Veliparib, Neoadjuvant and Second-Line Metastatic TNBC Settings 88
Table 34: Physicians Surveyed by Country 91

1.2 List of Figures
Figure 1: Global Sales ($m) for HER2-Negative Breast Cancer by Region, 2013-2023 12
Figure 2: Global Sales for HER2-Negative Breast Cancer by Drug, 2013-2022 13
Figure 3: Global Sales ($m) of Branded Products for HER2-Negative Breast Cancer by Company*, 2013-2023 17
Figure 4: Company Portfolio Gap Analysis in HER2-Negative Breast Cancer 2013-2023 18